Food Allergy, Peanut Allergy
Conditions
Brief summary
The purpose of this trial is to assess the safety and efficacy of peanut immunotherapy in children and adults with peanut allergy. Participants will receive immunotherapy with peanut every 2 weeks for a period of 3 months.
Interventions
DRUGPeanut Immunotherapy
Treatment will be injected peanut extract every 2 weeks for a period of 3 months.
Sponsors
University Hospital, Geneva
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
1. Informed Consent as documented by signature. 2. Male or female subjects 12 to 45 years old at screening visit. 3. Patients with convincing history of IgE-mediated systemic allergic reaction after consumption of peanut, and specific IgE above 95% positive predictive value: a. Peanut ≥ 15kU/L or Ara h 2 ≥ 5U/L 4. Patients without a convincing history of IgE-mediated systemic allergic reaction (for example only oral symptoms) after consumption of peanuts but with clear evidence of sensitization (SPT \> 3 mm and/or positive specific IgE (\> 0.1kU/l) and a positive standardized food challenge to peanut between V0 and V1.
Exclusion criteria
1. Subjects with a history of severe anaphylaxis to the incriminated food with the following symptoms: hypotension, hypoxia, neurological compromise (collapse, loss of consciousness or incontinence). 2. Subjects with a history of systemic reaction to peanutskin prick test with commercial extract. 3. Uncontrolled asthma (Forced expiratory volume at one second (FEV1) \<70% of predicted value), active eosinophilic oesophagitis or any condition deemed incompatible by the investigator. 4. Known or suspected systemic mastocytosis. 5. Subject currently under allergen immunotherapy. 6. Subject/parent with excessive anxiety unlikely to cope with study conditions as per investigator's opinion. 7. Participation in a clinical study with a new investigational drug within the last 3 months or for a biological within the last 6 months prior to or during the study. 8. Use of immunosuppression or immunomodulatory drug (including anti-IgE or anti-Tumor necrosis factor (TNF)) within 1 year prior to inclusion in study. 9. Relative counter-indication or inability to use epinephrine auto-injector. 10. Subjects receiving beta-blockers or angiotensin converting-enzyme (ACE) inhibitors. 11. Women who are pregnant or breast feeding. 12. Intention to become pregnant during the course of the study, or inadequate contraceptive measures for women of child-bearing age (contraceptive measures considered adequate are: intrauterine devices, hormonal contraceptives, such as contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release). 13. Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.). 14. Diseases with a contraindication for the use of adrenalin (e.g. hyperthyroidism, glaucoma). 15. Known or suspected non-compliance, drug or alcohol abuse. 16. Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant. 17. Patients who are employees of the sponsor, institution or 1st grade relatives or partners of the investigators
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Result (positive or negative) and cumulative reaction threshold at 3 months peanut oral food challenge (OFC). | 3 months | An unblinded evaluation of peanut OFC cumulative reaction threshold after 3 months of peanut immunotherapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in serum levels of allergen specific IgE and IgG4 after 6 weeks and 3 months of treatment compared to baseline peanut specific IgE and IgG4 after 3 months of treatment with peanut extract. | 3 months | An evaluation of changes in serum levels of allergen specific IgE and IgG4 after 6 weeks and 3 months of treatment compared to baseline peanut specific IgE and IgG4 after 3 months of treatment with peanut extract. |
| Change in titrated skin prick test after 6 weeks and 3 months of treatment with peanut extract compared to baseline. | 3 months | An evaluation of changes in titrated skin prick tests after 6 weeks and 3 months of treatment with peanut extract compared to baseline. |
| Incidence rate of treatment emergent adverse events during peanut immunotherapy | 3 months | An unblinded evaluation of the safety of peanut immunotherapy as measured by the incidence of treatment-emergent adverse events (AEs and SAEs). |
Countries
Switzerland
Outcome results
None listed